Skip to content
DataLookout
Menu

SPINERECTORNCT06200298

Effectiveness of Erector Spinae Plane Block for Percutaneous Arthrodesis of Spinal Fractures

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words Show 4 more changesShow less
    • Trial completed
    • Enrollment target: estimated 86 to confirmed 79
    • Study completion date changed from estimate of Sep 2026 to Sep 29, 2026
    • Interventions: ESPB with saline 0,9% (Procedure), Erector spinae plane block with naropeine [3,75 mg/mL] (Procedure) to ESPB with saline 0,9% (Procedure), Erector spinae plane block with naropeine [3,75 mg/mL] (Procedure)
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Jul 2026 to Apr 25, 2026
    • Study completion date: Jul 2026 to Sep 2026
    • Site details revised
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 10, 2024 to Apr 11, 2024
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Morphine consumption for the first postoperative 24 hours
Timeframe: during the first 24H after the procedure

Secondary (8)

intraoperative morphine consumption
Evolution of postoperative morphine consumption 1 hour
Evolution of postoperative morphine consumption 3 hours
Evolution of postoperative morphine consumption 6 hours
Evolution of postoperative morphine consumption 9 hours
Show 3 moreShow less
Evolution of postoperative morphine consumption 12 hour
Evolution of postoperative pain
Duration of stay in postanesthesia care unit (PACU)

Arms and interventions

Erector spinae plane block with naropeine [3,75 mg/mL]Experimental

Experimental group: Erector spinae plane block with naropeine \[3,75 mg/mL\]

Control group : ESPB with saline 0,9%Active comparator

Procedures: Erector spinae plane block with naropeine [3,75 mg/mL], ESPB with saline 0,9%

Sites

1 site in 1 country

  • Hôpital Roger SalengroLille, France